Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Review

Glutamine at focus: versatile roles in cancer

Authors: Humberto De Vitto, Juan Pérez-Valencia, James A. Radosevich

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

During the past decade, a heightened understanding of metabolic pathways in cancer has significantly increased. It is recognized that many tumor cells are genetically programmed and have involved an abnormal metabolic state. Interestingly, this increased metabolic autonomy generates dependence on various nutrients such as glucose and glutamine. Both of these components participate in various facets of metabolic activity that allow for energy production, synthesis of biomass, antioxidant defense, and the regulation of cell signaling. Here, we outline the emerging data on glutamine metabolism and address the molecular mechanisms underlying glutamine-induced cell survival. We also discuss novel therapeutic strategies to exploit glutamine addiction of certain cancer cell lines.
Literature
1.
2.
Warburg O, Posener K. Ueber den Stoffwechsel der Carcinomzelle. Naturwissenschaften. 1924;12:1131–7.CrossRef
3.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.PubMedCrossRef
4.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.PubMedPubMedCentralCrossRef
5.
6.
Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12(11):829–46.PubMedCrossRef
7.
8.
9.
Csibi A, Lee G, Yoon SO, Tong H, Ilter D, Elia I, et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol. 2014;24(19):2274–80.PubMedPubMedCentralCrossRef
10.
Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One. 2009;4(3), e4715.PubMedPubMedCentralCrossRef
11.
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5.PubMedPubMedCentralCrossRef
12.
Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481(7381):380–4.
13.
Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–5.PubMedPubMedCentralCrossRef
14.
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782–7.PubMedPubMedCentralCrossRef
15.
Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178(1):93–105.PubMedPubMedCentralCrossRef
16.
Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–84.PubMedPubMedCentralCrossRef
17.
DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104(49):19345–50.PubMedPubMedCentralCrossRef
18.
Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol. 2015;17(12):1556–68.PubMedPubMedCentralCrossRef
19.
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014;10:728.PubMedPubMedCentralCrossRef
20.
Zhang J, Fan J, Venneti S, Cross J, Takagi T, Bhinder B, et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell. 2014;56(2):205–18.PubMedPubMedCentralCrossRef
21.
22.
Sauer L, Stayman J, Dauchy R. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res. 1982;2(10):4090–7.
23.
Bergström J, Fürst P, Norée L, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol. 1974;36(6):693–7.PubMed
24.
Reitzer L, Wice B, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979;254(8):2669–76.PubMed
25.
Witte D, Ali N, Carlson N, Younes M. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res. 2002;22(5):2555–7.PubMed
26.
Hassanein M, Hoeksema M, Shiota M, Qian J, Harris B, Chen H, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res. 2013;9(3):560–70.CrossRef
27.
Huang F, Zhao Y, Zhao J, Wu S, Jiang Y, Ma H, et al. Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. Int J Clin Exp Pathol. 2014;7(9):6006–14.PubMedPubMedCentral
28.
Wang Q, Hardie R, Hoy A, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-Mediated Glutamine Uptake Blocks Prostate Cancer Growth and Tumour Development. J Pathol. 2015. doi:10.​1002/​path.​4518.
29.
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521–34.PubMedPubMedCentralCrossRef
30.
Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell. 2015;9(27):354–69.CrossRef
31.
Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal. 2010;3(119):ra31.PubMedCrossRef
32.
Wellen K, Lu C, Mancuso A, Lemons J, Ryczko M, Dennis J, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 2010;24(24):2784–99.PubMedPubMedCentralCrossRef
33.
DeBerardinis RJ, Cheng T. Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29(3):313–24.PubMedCrossRef
34.
Bröer A, Wagner C, Lang F, Bröer S. The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem J. 2000;1(349):787–95.CrossRef
35.
Timmerman L, Holton T, Yuneva M, Louie R, Padró M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–65.PubMedPubMedCentralCrossRef
36.
Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986–93.PubMedPubMedCentralCrossRef
37.
Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2011;481(7381):385–8.PubMedPubMedCentral
38.
Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A. 2011;108(49):19611–6.PubMedPubMedCentralCrossRef
39.
Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44.PubMedPubMedCentralCrossRef
40.
Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491(7424):364–73.PubMedCrossRef
41.
Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497(7451):633–7.PubMedPubMedCentralCrossRef
42.
Shih C, Shilo B, Goldfarb M, Dannenberg A, Weinberg R. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A. 1979;76(11):5714–8.PubMedPubMedCentralCrossRef
43.
Spector D, Varmus H, Bishop J. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc Natl Acad Sci U S A. 1978;75(9):4102–6.PubMedPubMedCentralCrossRef
44.
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–82.PubMedCrossRef
45.
Medina M, Sánchez-Jiménez F, Márquez J, Rodríguez Quesada A. Núñez de Castro I. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem. 1992;113(1):1–15.PubMedCrossRef
46.
Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18(3):207–19.PubMedPubMedCentralCrossRef
47.
Cheng T, Sudderth J, Yang C, Mullen A, Jin E, Matés J, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A. 2011;24(108):8674–9.CrossRef
48.
Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012;22(5):631–44.PubMedPubMedCentralCrossRef
49.
Terunuma A, Putluri N, Mishra P, Mathé E, Dorsey T, Yi M, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014;124(1):398–412.PubMedCrossRef
50.
Bott AJ, Peng IC, Fan Y, Faubert B, Zhao L, Li J, et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 2015;22(6):1068–77.PubMedPubMedCentralCrossRef
51.
Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet. 2011;8, e1002229.CrossRef
52.
McCormick F. Ras-related proteins in signal transduction and growth control. Mol Reprod Dev. 1995;42(4):500–6.PubMedCrossRef
53.
Chiaradonna F, Gaglio D, Vanoni M, Alberghina L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochim Biophys Acta. 2006;1757(9-10):1338–56.PubMedCrossRef
54.
Chiaradonna F, Sacco E, Manzoni R, Giorgio M, Vanoni M, Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene. 2006;25(39):5391–404.PubMedCrossRef
55.
Vizan P, Boros L, Figueras A, Capella G, Mangues R, Bassilian S, et al. K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res. 2005;65(13):5512–5.PubMedCrossRef
56.
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325(5947):1555–9.PubMedPubMedCentralCrossRef
57.
Weinberg F, Hamanaka R, Wheaton W, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107(19):8788–93.PubMedPubMedCentralCrossRef
58.
Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.PubMedPubMedCentralCrossRef
59.
Kong B, Qia C, Erkan M, Kleeff J, Michalski CW. Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Front Physiol. 2013;4:246.PubMedPubMedCentralCrossRef
60.
Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628–32.PubMedPubMedCentralCrossRef
61.
Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, et al. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab. 2015;3(12). doi:10.​1186/​s40170-015-0137-1.
62.
63.
Bensaad K, Tsuruta A, Selak M, Vidal M, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–20.PubMedCrossRef
64.
Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650–3.PubMedCrossRef
65.
Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107(16):7455–60.PubMedPubMedCentralCrossRef
66.
Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature. 2013;493(7434):689–93.PubMedPubMedCentralCrossRef
67.
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107(16):7461–6.PubMedPubMedCentralCrossRef
68.
Szeliga M, Obara-Michlewska M, Matyja E, Łazarczyk M, Lobo C, Hilgier W, et al. Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia. 2009;57(9):1014–23.PubMedCrossRef
69.
Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, Kong M. The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell. 2013;50(2):200–11.PubMedCrossRef
70.
71.
Haigis M, Guarente L. Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20(21):2913–21.PubMedCrossRef
72.
73.
Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23(4):450–63.PubMedPubMedCentralCrossRef
74.
Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2013;153(4):840–54.PubMedPubMedCentralCrossRef
75.
Cetinbas N, Daugaard M, Mullen AR, Hajee S, Rotblat B, Lopez A, et al. Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction. Oncogene. 2014.
76.
Menon S, Manning B. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008; Suppl 2:S43–51.
77.
Bentzinger C, Romanino K, Cloëtta D, Lin S, Mascarenhas J, Oliveri F, et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008;5:411–24.CrossRef
78.
Elstrom R, Bauer D, Buzzai M, Karnauskas R, Harris M, Plas D, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–9.PubMedCrossRef
79.
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey R, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15(11):1406–18.PubMedPubMedCentralCrossRef
80.
81.
Gingras A, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15(7):807–26.PubMedCrossRef
82.
Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E, et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell. 2012;47(3):349–58.PubMedCrossRef
83.
Shanware NP, Bray K, Eng CH, Wang F, Follettie M, Myers J, et al. Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. Nat Commun. 2014;5:4900.PubMedPubMedCentralCrossRef
84.
Onul A, Elseth K, De Vitto H, Paradise W, Vesper B, Tarjan G, et al. Long-term adaptation of the human lung tumor cell line A549 to increasing concentrations of hydrogen peroxide. Tumour Biol. 2012;33(3):739–48.PubMedCrossRef
85.
Vesper B, Onul A, Haines GR, Tarjan G, Xue J, Elseth K, et al. Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines. Tumour Biol. 2013;24(1):203–14.CrossRef
86.
87.
Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell. 2015;162(2):259–70.PubMedPubMedCentralCrossRef
88.
Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–62.PubMedCrossRef
89.
Davies S, Sim A, Hardie D. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem. 1990;187(1):183–90.PubMedCrossRef
90.
Gwinn D, Shackelford D, Egan D, Mihaylova M, Mery A, Vasquez D, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214–26.PubMedPubMedCentralCrossRef
91.
92.
Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17(1):113–24.PubMedCrossRef
93.
Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature. 2012;483(7391):608–12.PubMedCrossRef
94.
Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, et al. Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis. Cell. 2013;152(3):599–611.PubMedPubMedCentralCrossRef
95.
96.
97.
De Vitto H, Mendonça B, Elseth K, Onul A, Xue J, Vesper B, et al. Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism. Tumour Biol. 2013;34(1):403–13.PubMedCrossRef
98.
Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17–29.PubMedPubMedCentralCrossRef
99.
Tu BP, Mohler RE, Liu JC, Dombek KM, Young ET, Synovec RE, et al. Cyclic changes in metabolic state during the life of a yeast cell. Proc Natl Acad Sci U S A. 2007;104(23):16886–91.PubMedPubMedCentralCrossRef
100.
Dasgupta S, Soudry E, Mukhopadhyay N, Shao C, Yee J, Lam S, et al. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol. 2012;227(6):2451–60.PubMedPubMedCentralCrossRef
101.
Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer. 2005;11:857–66.CrossRef
102.
King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675–82.PubMedCrossRef
103.
Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2015;29(8):887.PubMedPubMedCentral
104.
Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477(7363):225–8.PubMedCrossRef
105.
Rajagopalan KN, Egnatchik RA, Calvaruso MA, Wasti AT, Padanad MS, Boroughs LK, et al. Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells. Cancer Metab. 2015;3:7.PubMedPubMedCentralCrossRef
106.
Chowdhury R, Yeoh K, Tian Y, Hillringhaus L, Bagg E, Rose N, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463–9.PubMedPubMedCentralCrossRef
107.
Lu C, Ward P, Kapoor G, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–8.PubMedPubMedCentralCrossRef
108.
Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–34.PubMedPubMedCentralCrossRef
109.
Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111–6.PubMed
110.
Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw A, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005;8(4):311–21.PubMedCrossRef
111.
Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491(7424):458–62.PubMedPubMedCentralCrossRef
112.
Méndez-Lucas A, Hyroššová P, Novellasdemunt L, Viñals F, Perales JC. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) is a pro-survival, endoplasmic reticulum (ER)stress response gene involved in tumor cell adaptation to nutrient availability. J Biol Chem. 2014;289(32):22090–102.PubMedPubMedCentralCrossRef
113.
Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, et al. PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth. Mol Cell. 2015;60(4):571–83.PubMedPubMedCentralCrossRef
114.
Klarer AC, O’Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab. 2014;2(1):2.PubMedPubMedCentralCrossRef
115.
Berg J, Tymoczko J, Stryer L. The glycolytic pathway is tightly controlled. biochemistry. 5th ed. New York, USA: W H Freeman; 2002.
116.
Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;9(4):191–8.CrossRef
117.
Possemato R, Marks K, Shaul Y, Pacold M, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346–50.PubMedPubMedCentralCrossRef
118.
119.
Locasale J, Grassian A, Melman T, Lyssiotis C, Mattaini K, Bass A, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869–74.PubMedPubMedCentralCrossRef
120.
Maddocks O, Berkers C, Mason S, Zheng L, Blyth K, Gottlieb E, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493(7433):542–6.PubMedCrossRef
121.
Amelio I, Markert E, Rufini A, Antonov A, Sayan B, Tucci P, et al. p73 regulates serine biosynthesis in cancer. Oncogene. 2014;33(42):5039–46.PubMedCrossRef
122.
Duthie S. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis. 2011;34(1):101–9.PubMedCrossRef
123.
Piskac-Collier A, Monroy C, Lopez M, Cortes A, Etzel C, Greisinger A, et al. Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer. 2011;50(1):1–12.PubMedCrossRef
124.
Farber S, Diamond L, Mercer R, Sylvester R, Wolff J. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238:787–93.PubMedCrossRef
125.
Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2010;3(1):23–34.PubMedPubMedCentralCrossRef
126.
Holmström K, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol. 2014;15(6):411–21.PubMedCrossRef
127.
Cooke M, Evans M, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195–214.PubMedCrossRef
128.
129.
Valko M, Rhodes C, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40.PubMedCrossRef
130.
Amores-Sánchez M, Medina M. Glutamine, as a precursor of glutathione, and oxidative stress. Mol Genet Metab. 1999;67(2):100–5.PubMedCrossRef
131.
Roth E, Oehler R, Manhart N, Exner R, Wessner B, Strasser E, et al. Regulative potential of glutamine—relation to glutathione metabolism. Nutrition. 2002;18(3):217–21.PubMedCrossRef
132.
Estrela J, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006;43(2):143–81.PubMedCrossRef
133.
Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez M, García-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013;65:750–64.PubMedCrossRef
134.
Hayes J, McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell. 2006;21(6):732–4.PubMedCrossRef
135.
Kensler T, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010;31(1):90–9.PubMedCrossRef
136.
137.
Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22(1):66–79.PubMedCrossRef
138.
Afonyushkin T, Oskolkova OV, Philippova M, Resink TJ, Erne P, Binder BR, et al. Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependentmechanism: novel point of convergence between electrophilic and unfolded protein stress pathways. Arterioscler Thromb Vasc Biol. 2010;30(5):1007–13.PubMedCrossRef
139.
He CH, Gong P, Hu B, Stewart D, Choi ME, Choi AM, et al. Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J Biol Chem. 2001;276(24):20858–65.PubMedCrossRef
140.
DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2015;47(12):1475–81.PubMedPubMedCentralCrossRef
141.
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931–47.PubMedCrossRef
142.
143.
144.
DeBerardinis R, Lum J, Hatzivassiliou G, Thompson C. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;1:11–20.CrossRef
145.
Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle. 2014;9(19):3921–32.CrossRef
146.
Eng C, Abraham R. Glutaminolysis yields a metabolic by-product that stimulates autophagy. Autophagy. 2010;7:968–70.CrossRef
147.
Mariño G, Kroemer G. Ammonia: a diffusible factor released by proliferating cells that induces autophagy. Sci Signal. 2010;124:pe19.
148.
Cheong H, Lindsten T, Thompson C. Autophagy and ammonia. Autophagy. 2012;1:122–3.CrossRef
149.
150.
Weinberg S, Chandel N. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;1:9–15.
151.
Ahluwalia G, Grem J, Hao Z, Cooney D. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990;46(2):243–71.PubMedCrossRef
152.
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–21.PubMedPubMedCentralCrossRef
153.
Seltzer M, Bennett B, Joshi A, Gao P, Thomas A, Ferraris D, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70(22):8981–7.PubMedPubMedCentralCrossRef
154.
Thornburg J, Nelson K, Clem B, Lane A, Arumugam S, Simmons A, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 2008;10(5):R84.PubMedPubMedCentralCrossRef
155.
Stalnecker C, Ulrich SL Y, Ramachandran S, McBrayer M, DeBerardinis R, Cerione R, et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci U S A. 2015;112(2):394–9.PubMedCrossRef
156.
Narta U, Kanwar S, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61(3):208–21.PubMedCrossRef
157.
158.
159.
Li B, Simon MC. Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res. 2013;1:19(21). doi:10.​1158/​1078-0432.
160.
Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila). 2010;3(8):900–9.CrossRef
161.
Qu W, Oya S, Lieberman BP, Ploessl K, Wang L, Wise DR, et al. Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors. J Nucl Med. 2012;53(1):98–105.PubMedCrossRef
162.
Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med. 2011;52(12):1947–55.PubMedCrossRef
163.
Venneti S, Dunphy M, Zhang H, Pitter K, Zanzonico P, Campos C, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med. 2015;7(274):274ra17.PubMedPubMedCentralCrossRef
164.
165.
Metallo C, Walther J, Stephanopoulos G. Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells. J Biotechnol. 2009;144(3):167–74.PubMedPubMedCentralCrossRef
166.
Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157–70.PubMedPubMedCentralCrossRef
167.
Mayers J, Vander HM. Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem Sci. 2015.
168.
Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75(3):544–53.PubMedPubMedCentralCrossRef
Metadata
Title
Glutamine at focus: versatile roles in cancer
Authors
Humberto De Vitto
Juan Pérez-Valencia
James A. Radosevich
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4671-9

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

iTRAQ-based quantitative proteomic analysis of esophageal squamous cell carcinoma

Original Article

Neo-epitopes on crotonaldehyde modified DNA preferably recognize circulating autoantibodies in cancer patients

Erratum

Erratum to: Abstract supplement The 42nd Congress of the International Society of Oncology and Biomarkers “ONOCOLOGY IN THE BIOMARKER ERA: Biology – Diagnostics – Therapy” ISOBM 2015

Original Article

Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells

Review

Serum microRNAs as potential noninvasive biomarkers for glioma

Original Article

Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits